And its subsidiary.

Cantrixil proves highly effective at killing human being ovarian stem cells in pre-clinical study US-Australian drug discovery business, Novogen Ltd, and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-medical data on experimental anti-cancer medication, Cantrixil. The info was offered as an oral display by Professor Gil Mor MD PhD of Yale Medical College to the 62nd Annual Scientific Interacting with of the Culture of Reproductive Investigation in San Francisco, CA . In both in vitro and in pet research, Cantrixil, has proved highly effective at killing individual ovarian stem cells, cells that normally are highly resistant to standard of care cytotoxic medications and which generally are believed to be responsible for diseases recurrence following preliminary therapy.

1. In future months, consumers would have to enroll by the 15th of the month for insurance coverage to begin on the 1st of the next month. Open enrollment proceeds until March 31′ . Browse the rest of the whole story. This content was reprinted from with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is a program of the Kaiser Family Foundation, a nonpartisan healthcare policy research organization unaffiliated with Kaiser Permanente. Related StoriesSurgical startup seeks financing to build virtual reality teaching libraryGenetic carrier screening: an interview with Don Hardison, CEO of Good Start GeneticsRE.WORK showcases future improvements and technology in deep learning software ..